Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Neighbourly Pharmacy Inc T.NBLY.R


Primary Symbol: T.NBLY

Neighbourly Pharmacy Inc. is a Canada-based company that operates a network of community pharmacies. The Company is an owner and operator of retail pharmacies located throughout Canada under banners such as IDA/Guardian, Pharmachoice, Pharmasave and Remedy’s RX. The Company, through its subsidiaries, owns and operates a network of retail pharmacies known as Rubicon Pharmacies (Rubicon or Rubicon Pharmacies. The Company owns and operates approximately 287 locations across seven provinces and one territory, a coast-to-coast footprint that provides scale and diversification. The Company’s pharmacies provide accessible healthcare with a personal touch. The Company also owns British Columbia-based pharmacies.


TSX:NBLY - Post by User

Comment by Possibleidiot01on Dec 20, 2023 7:32pm
201 Views
Post# 35794871

RE:Trevor Rose's Insights -Comment- Revised Deal

RE:Trevor Rose's Insights -Comment- Revised Deal Updated tonight.

RISKY
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research The company has only been public for 30 months, so management is still on probation, at least publicly. The recent privatization 'flip flop' certainly docks them some points. And, having gone public at $17 and then (proposed) private at $18.50 doesn't make that much business sense to us. BUT...management likely sees the potential for the future moreso than investors, and we can't blame them for trying to take advantage of the low price in the market if prospects are so good. It leaves a bad taste, sure, but that's business. In a failed deal we would expect the stock to drop to the $14 range. The difference vs prior is due to the much improved market/rate backdrop. It will still have potential from there, certainly, but it is sometimes difficult for shareholders to support a management team that clearly 'wants to go private'. Thus, we would not expect a huge uptick in valuation multiples, but it could still do well with organic growth and acquisitions.


<< Previous
Bullboard Posts
Next >>